Light-intensity and moderate-to-vigorous intensity physical activity among older adult breast cancer survivors with obesity: A narrative review.
aged, health promotion
breast neoplasms
exercise
obesity
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
revised:
26
04
2022
received:
02
02
2022
accepted:
02
05
2022
pubmed:
28
5
2022
medline:
15
12
2022
entrez:
27
5
2022
Statut:
ppublish
Résumé
With an aging population, rising incidence of breast cancer, improved survival rates, and obesity epidemic, there will be a growing population of older adult breast cancer survivors with obesity. This complex population, often with multimorbidity, is at risk for several poor health outcomes, including recurrence, cardiovascular disease, dementia, and diabetes, and a number of deleterious symptoms, including a worsened inflammatory profile, breast cancer- related lymphedema, mobility disability, cognitive impairment, anxiety, and depressive symptoms. A wealth of meta-analytic and randomized controlled trial evidence show that adherence to World Health Organization and 2018 United States Physical Activity guidelines-based levels of moderate-to-vigorous physical activity (MVPA) reduces risk of all-cause mortality, and improves symptoms. However, few survivors engage in recommended levels of MVPA, and symptoms related to their multimorbidity may preclude engaging in sufficient levels of MVPA. Additional research of MVPA in this population is warranted; however, understudied light-intensity physical activity (LIPA) may be a more pragmatic target than MVPA among this complex population facing extensive challenges meeting MVPA recommendations. Large benefits are likely to occur from increasing these survivors' total activity, and LIPA prescriptions may be a more pragmatic approach than MVPA to aid this transition. We present a broad, narrative review of the evidence for MVPA and LIPA in this population on an array of health outcomes across the translational science spectrum (clinical, implementation, and public health), and identify a number of directions for future research focused on understanding the potential diverse health effects of LIPA. Additional LIPA research is warranted, as LIPA prescriptions may be a pragmatic strategy to effectively promote physical activity to this complex population.
Sections du résumé
BACKGROUND
BACKGROUND
With an aging population, rising incidence of breast cancer, improved survival rates, and obesity epidemic, there will be a growing population of older adult breast cancer survivors with obesity. This complex population, often with multimorbidity, is at risk for several poor health outcomes, including recurrence, cardiovascular disease, dementia, and diabetes, and a number of deleterious symptoms, including a worsened inflammatory profile, breast cancer- related lymphedema, mobility disability, cognitive impairment, anxiety, and depressive symptoms. A wealth of meta-analytic and randomized controlled trial evidence show that adherence to World Health Organization and 2018 United States Physical Activity guidelines-based levels of moderate-to-vigorous physical activity (MVPA) reduces risk of all-cause mortality, and improves symptoms. However, few survivors engage in recommended levels of MVPA, and symptoms related to their multimorbidity may preclude engaging in sufficient levels of MVPA. Additional research of MVPA in this population is warranted; however, understudied light-intensity physical activity (LIPA) may be a more pragmatic target than MVPA among this complex population facing extensive challenges meeting MVPA recommendations. Large benefits are likely to occur from increasing these survivors' total activity, and LIPA prescriptions may be a more pragmatic approach than MVPA to aid this transition.
METHODS
METHODS
We present a broad, narrative review of the evidence for MVPA and LIPA in this population on an array of health outcomes across the translational science spectrum (clinical, implementation, and public health), and identify a number of directions for future research focused on understanding the potential diverse health effects of LIPA.
CONCLUSION
CONCLUSIONS
Additional LIPA research is warranted, as LIPA prescriptions may be a pragmatic strategy to effectively promote physical activity to this complex population.
Identifiants
pubmed: 35620805
doi: 10.1002/cam4.4841
pmc: PMC9741972
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
4602-4611Subventions
Organisme : NCI NIH HHS
ID : K07/CA215937
Pays : United States
Organisme : American Cancer Society
ID : MSRG/18-136-01-CPPB
Organisme : Four Diamonds
Organisme : NCI NIH HHS
ID : F32 CA247263
Pays : United States
Organisme : NIA NIH HHS
ID : R00/AG056670
Pays : United States
Organisme : NCI NIH HHS
ID : F32/CA247263
Pays : United States
Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Am Geriatr Soc. 2013 Mar;61(3):452-3
pubmed: 23496180
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Am J Prev Med. 2011 Aug;41(2):174-7
pubmed: 21767725
BMC Cancer. 2021 May 30;21(1):643
pubmed: 34053445
Psychooncology. 2006 May;15(5):422-30
pubmed: 16097037
J Clin Oncol. 2005 Mar 1;23(7):1370-8
pubmed: 15684320
Breast Cancer Res Treat. 2018 Jan;167(1):133-145
pubmed: 28856470
Clin J Oncol Nurs. 2015 Apr;19(2):213-7
pubmed: 25840387
JMIR Cancer. 2021 Apr 13;7(2):e18819
pubmed: 33847588
Med Sci Sports Exerc. 2017 Aug;49(8):1572-1582
pubmed: 28272267
Med Clin North Am. 2012 Jan;96(1):87-91
pubmed: 22391253
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):1067-1073
pubmed: 32303534
Exerc Sport Sci Rev. 2010 Jan;38(1):17-24
pubmed: 20016295
Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390
pubmed: 31626055
Int J Environ Res Public Health. 2019 Mar 05;16(5):
pubmed: 30841555
Depress Anxiety. 2015 Aug;32(8):624-34
pubmed: 25899389
JAMA Netw Open. 2019 Jul 3;2(7):e197597
pubmed: 31348504
Med Sci Sports Exerc. 2010 Jul;42(7):1409-26
pubmed: 20559064
J Natl Cancer Inst. 2006 Apr 19;98(8):521-9
pubmed: 16622121
Breast Cancer Res Treat. 2010 Apr;120(3):525-38
pubmed: 20157776
Health Qual Life Outcomes. 2019 Jan 18;17(1):17
pubmed: 30658629
Cochrane Database Syst Rev. 2018 Jan 29;1:CD011292
pubmed: 29376559
J Neurol Neurosurg Psychiatry. 2005 Dec;76 Suppl 5:v2-7
pubmed: 16291918
J Adv Pract Oncol. 2020 Mar;11(2):135-136
pubmed: 33532112
Qual Health Res. 2009 Jul;19(7):894-906
pubmed: 19448032
Brain Res. 2012 May 9;1453:87-101
pubmed: 22480735
Oncology (Williston Park). 2018 Aug 15;32(8):410-7
pubmed: 30153321
CA Cancer J Clin. 2019 Nov;69(6):438-451
pubmed: 31577379
CA Cancer J Clin. 2020 Jul;70(4):245-271
pubmed: 32515498
Cancer. 2021 Feb 1;127(3):476-484
pubmed: 33090477
JAMA Netw Open. 2019 Apr 5;2(4):e192745
pubmed: 31002329
Int J Behav Nutr Phys Act. 2014 Jul 02;11:80
pubmed: 24989069
BMC Cancer. 2020 Feb 20;20(1):113
pubmed: 32075592
JNCI Cancer Spectr. 2019 Oct 17;4(1):pkz080
pubmed: 32337494
BMJ. 2013 Nov 20;347:f6753
pubmed: 24259324
Crit Rev Oncol Hematol. 2007 Apr;62(1):84-91
pubmed: 17188505
BMJ. 2005 Mar 26;330(7493):702
pubmed: 15695497
Med Sci Sports. 1978 Fall;10(3):vii-x
pubmed: 723501
Bone. 2014 Jul;64:254-62
pubmed: 24735973
PeerJ. 2015 Nov 26;3:e1437
pubmed: 26644978
Ann Behav Med. 2008 Feb;35(1):116-22
pubmed: 18347912
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
JAMA. 2016 Feb 2;315(5):457-8
pubmed: 26746707
J Aging Phys Act. 2019 Nov 6;28(2):311-319
pubmed: 31693992
Psychooncology. 2019 Jul;28(7):1381-1393
pubmed: 31041830
Int J Behav Nutr Phys Act. 2011 Nov 02;8:121
pubmed: 22047024
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
Lymphology. 2006 Dec;39(4):185-92
pubmed: 17319631
Contemp Clin Trials. 2016 Jan;46:106-113
pubmed: 26655430
J Clin Med. 2021 Feb 18;10(4):
pubmed: 33670615
Cancer Med. 2022 Dec;11(23):4602-4611
pubmed: 35620805
CA Cancer J Clin. 2018 Jan;68(1):64-89
pubmed: 29165798
JAMA Oncol. 2022 Mar 01;8(3):395-403
pubmed: 34989765
J Cancer Surviv. 2013 Sep;7(3):493-9
pubmed: 23686709
Curr Oncol Rep. 2019 Mar 27;21(5):41
pubmed: 30919143
PLoS One. 2017 Aug 14;12(8):e0182554
pubmed: 28806753
Med Sci Sports Exerc. 2016 Jul;48(7):1303-11
pubmed: 26848889
Support Care Cancer. 2019 Dec;27(12):4435-4450
pubmed: 31418074